Psoralidin 是COX-2和5-LOX的双重抑制剂。具有抗癌，抗菌和抗炎作用。Psoralidin 显著下调NOTCH1信号传导。Psoralidin 还极大地诱导ROS产生。
| 生物活性 | Psoralidin is a dual inhibitor ofCOX-2and5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.Anti-cancer, anti-bacterial, and anti-inflammatory properties[1]. Psoralidin significantly downregulatesNOTCH1signaling. Psoralidin also greatly inducesROSgeneration[2]. |
| IC50& Target[1] | |
体外研究
(In Vitro) | Three breast cancer cell (BCC)populations (ALDH-cells, ALDH+cells, and commercial BSCSs) are sensitive to Psoralidin treatment (10, 15, 20, and 25 μM; 24 hours) with IC50s ranging from 18 to 21 μM; however, the MCF-12A cells were resistant to Psoralidin[2].
Psoralidin (30 μM; 24 hours) results in a significant induction of apoptosis for ALDH-cells, ALDH+cells, and commercial BCSCs[2].
Psoralidin treatment also downregulates NOTCH1 expression in both ALDH-and ALDH+cells[2].
Cell Viability Assay[2] | Cell Line: | ALDH-cells, ALDH+cells, commercial breast cancer stem cells (BSCSs), and normal breast epithelial cells (MCF-12A) | | Concentration: | 10, 15, 50, and 25 μM | | Incubation Time: | 24 hours | | Result: | IC50s of 18 to 21 μM for ALDH-cells, ALDH+cells, commercial BCSCs. |
Apoptosis Analysis[2] | Cell Line: | ALDH-cells, ALDH+cells, and commercial BCSCs | | Concentration: | 20 and 30 μM | | Incubation Time: | 24 hours | | Result: | No significant induction of apoptosis was observed for any of the three cell types following treatment at 20 μM. However, 53.60%, 44.1%, and 45.9% of cells were apoptotic at 30 μMin ALDH-cells, ALDH+cells, and commercial BCSCs, respectively. |
|
体内研究
(In Vivo) | Psoralidin (5 mg/kg) regulates expression of pro-inflammatory cytokines that play an important role in inflammatory diseasesin IR-irradiated lung of BALB/c mouse[1].
| Animal Model: | BALB/c mice[1] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal application; 30 min before and 1 h after IR irradiation (20 Gy). | | Result: | Anti-inflammatory effect in IR-irradiated mice. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 结构分类 | |
| 来源 | - Plants
- Leguminosae
- Psoralea corylifoliaL.
|
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | | Powder | -20°C | 3 years | | 4°C | 2 years | | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
| 溶解性数据 | In Vitro: DMSO : 50 mg/mL(148.66 mM;ultrasonic and warming and heat to 60℃) 配制储备液 | 1 mM | 2.9732 mL | 14.8659 mL | 29.7318 mL | | 5 mM | 0.5946 mL | 2.9732 mL | 5.9464 mL | | 10 mM | 0.2973 mL | 1.4866 mL | 2.9732 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.08 mg/mL (6.18 mM); Suspended solution; Need ultrasonic
此方案可获得 2.08 mg/mL (6.18 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (6.18 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (6.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
